Comparative Pharmacology
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
NEBCIN vs NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Gramicidin is a polypeptide antibiotic that increases cell membrane permeability by forming ion channels, leading to bacterial cell death.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
Instill 2 drops (or appropriate amount) into affected eye(s) every 2-4 hours for 7-10 days. Frequency may be increased to every 1-2 hours in severe infections. Ophthalmic suspension, not for injection.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Neomycin: 2-3 hours (normal renal function); polymyxin B: 6-8 hours; gramicidin: ~10 hours (estimated from topical absorption). Prolonged in renal impairment, especially for polymyxin B.
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Renal: ~95% for neomycin (unchanged), minimal for polymyxin B (1-10% unchanged) and gramicidin (<1%). Fecal: 50-60% for polymyxin B (biliary), ~1% for neomycin.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic